RecallRadar

FDA Device recall Z-1249-2025

Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal fa…

On 2025-03-12 the FDA classified a Class II recall of Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal fa… by Beckman Coulter, citing affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demon….

Read the official FDA Device notice

AgencyFDA Device
Recall numberZ-1249-2025
ClassificationClass II
Statusongoing
Initiated2025-02-03
Published2025-03-12
Last updated2026-09-13 11:57 UTC
CompanyBeckman Coulter
DistributionAL, AR, AZ, CA, CT, FL, ID, IL, IN, KS, MA, MI, NC, NE, NJ, NY, OH, OR, PA, TN, TX, UT, WA, WV

Product

Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal production of EPO is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of EPO in the circulation increases and this leads to increased production of red blood cells.

Reason

Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.

Identifiers

code_infoCatalog A16364 UDI-DI 15099590201838 Lot 439363

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:57 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-1249-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.